Details of the Drug

General Information of Drug (ID: DM3OBQF)

Drug Name
Belimumab
Synonyms Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN)
Indication
Disease Entry ICD 11 Status REF
Membranous glomerulonephritis N.A. Approved [1]
Systemic lupus erythematosus 4A40.0 Approved [2]
Affected Organisms
Humans and other mammals
ATC Code
L04AA26: Belimumab
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Antibody
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 19.4 days [3]
Metabolism
The drug is metabolized via proteolytic enzymes []
Cross-matching ID
UNII
73B0K5S26A
DrugBank ID
DB08879
TTD ID
D05IQX
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell-activating factor (TNFSF13B) TTWMIDN TN13B_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Belimumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Belimumab and Teriflunomide. Hyper-lipoproteinaemia [5C80] [5]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Belimumab and Tecfidera. Multiple sclerosis [8A40] [6]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Belimumab and Siponimod. Multiple sclerosis [8A40] [7]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Belimumab and Ocrelizumab. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Belimumab and Ozanimod. Multiple sclerosis [8A40] [9]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Belimumab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [10]
⏷ Show the Full List of 6 DDI Information of This Drug

References

1 [Membranous glomerulonephritis (MGN), ongoing studies]. G Ital Nefrol. 2017 Sep 28;34(5):113-118.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6887).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
6 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
7 Cerner Multum, Inc. "Australian Product Information.".
8 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]